These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 8100601)
1. Indications and relative indications for stem cell transplantation in non-Hodgkin's lymphoma. Stewart FM Leukemia; 1993 Jul; 7(7):1091-4. PubMed ID: 8100601 [TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma. Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091 [TBL] [Abstract][Full Text] [Related]
4. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A; J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703 [TBL] [Abstract][Full Text] [Related]
5. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. Philip T; Armitage JO; Spitzer G; Chauvin F; Jagannath S; Cahn JY; Colombat P; Goldstone AH; Gorin NC; Flesh M N Engl J Med; 1987 Jun; 316(24):1493-8. PubMed ID: 3295541 [TBL] [Abstract][Full Text] [Related]
6. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877 [TBL] [Abstract][Full Text] [Related]
7. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921 [TBL] [Abstract][Full Text] [Related]
8. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases]. Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021 [TBL] [Abstract][Full Text] [Related]
9. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159 [TBL] [Abstract][Full Text] [Related]
10. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557 [TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study. Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474 [TBL] [Abstract][Full Text] [Related]
12. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma. Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783 [TBL] [Abstract][Full Text] [Related]
13. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis. Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930 [TBL] [Abstract][Full Text] [Related]
14. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation. Demirer T; Ayli M; Fen T; Ozcan M; Arat M; Buyukberber S; Arslan O; Gurman G; Akan H; Ilhan O Bone Marrow Transplant; 2004 Nov; 34(9):781-6. PubMed ID: 15354206 [TBL] [Abstract][Full Text] [Related]
15. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group. Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723 [TBL] [Abstract][Full Text] [Related]
16. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH; Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607 [TBL] [Abstract][Full Text] [Related]
17. Role of autologous bone marrow transplantation in non-Hodgkin's lymphoma. Vose JM; Armitage JO Hematol Oncol Clin North Am; 1993 Jun; 7(3):577-90. PubMed ID: 8102135 [TBL] [Abstract][Full Text] [Related]
18. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells. van Besien K; Margolin K; Champlin R; Forman S Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395 [TBL] [Abstract][Full Text] [Related]
19. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon. Gryn J; Johnson E; Goldman N; Devereux L; Grana G; Hageboutros A; Fernandez E; Constantinou C; Harrer W; Viner E; Goldberg J Bone Marrow Transplant; 1997 Feb; 19(3):221-6. PubMed ID: 9028549 [TBL] [Abstract][Full Text] [Related]
20. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma. Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]